|
|
Article: Pharmacia receives FDA marketing clearance for GENOTROPIN(TM) for treatment of growth hormone deficiency in children.
- Article from:
- Business Wire
- Article date:
- August 28, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ohio--(BUSINESS WIRE)--Aug. 28, 1995--GENOTROPIN(TM) (somatropin (rDNA origin) for injection), a recombinant growth hormone developed by Pharmacia, received U.S. Food and Drug Administration (FDA) marketing clearance for the long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone. Recent studies indicate approximately one in every 3,500 children is growth hormone deficient.
Growth hormone deficiency is a life-long pituitary gland defect that alters metabolism and slows a child's growth. GENOTROPIN stimulates linear growth in children suffering from growth hormone insufficiency. If left untreated, ...